couter

VXUSVanguard Total International Stock ETF

Oct 1, 2026 — AZN.L: Patent expiry and biosimilar overhang for mature respiratory/cardiovascular products
Chart by TradingView

The schedule

  • Thu1Oct

    (Driven by AZN.L) As key respiratory and cardiovascular products approach patent expiry, AstraZeneca PLC faces an intensifying biosimilar overhang that could either be managed smoothly, keeping the stock near $13800, or prove more disruptive, dragging shares toward $13800.00 if erosion is faster than expected.

  • Sun15Nov

    (Driven by AZN.L) A pivotal late‑stage oncology Phase 3 readout will test AstraZeneca PLC’s leadership in cancer therapeutics, with compelling data potentially driving the stock from $13598.09 up toward $17000.00, while a negative or inconclusive result could knock it back toward $17000.00 as pipeline value is reassessed.

  • Thu31Dec

    (Driven by AZN.L) Full‑year 2026 results and AstraZeneca PLC’s initial 2027 guidance will reset the market’s multi‑year growth and margin expectations, with a confident outlook and visible pipeline catalysts supporting a path toward $17500.00 versus a more cautious tone likely keeping the stock closer to $14500.

  • Mon25Jan

    (Driven by RY.TO) The Q1 2027 earnings release will act as a key checkpoint on the North American credit cycle for RBC, starting from a more conservative base of about $222.0.

  • Sat30Jan

    (Driven by SU.TO) The Q4 2026 and full-year 2026 earnings release will consolidate Suncor’s performance for the year and introduce formal 2027 guidance on production, capex, and costs. If the company delivers robust free cash flow, meets its 2026 targets, and guides 2027 volumes and spending in line with prior strategic messages, shares could trade up toward $102.00; a miss on volumes, margin compression, or a more cautious 2027 outlook could pull the stock back toward $102.00.

  • Sat20Mar

    (Driven by BA.L) By late March 2027, NATO commitments and major defense budget decisions for 2027–2028 in core markets (UK, US, Europe, Indo-Pacific partners) should clarify the medium-term spending trajectory, with BAE Systems assumed at $2500.00 and a hawkish spending stance supporting a move to $2625.00 versus a softer path dragging shares back to $2300.00 by 2027-04-12.

Past

  • Sun20Sep

    (Driven by RY.TO) Into the Bank of Canada and Federal Reserve fall meetings, markets will reassess the late-2026 rate path, driving sensitivity in RBC shares around $286.0 via net interest margin expectations and credit cycle views.

  • Tue15Sep

    (Driven by SU.PA) By late Q3 2026, potential trade and tariff actions under President Trump targeting EU industrial and electrical equipment exports could create a major macro overhang for Schneider Electric, with a benign outcome allowing the stock to drift toward $285.00 and an adverse tariff shock risking a pullback toward $285.00 from $276.00.

  • Thu27Aug

    (Driven by RY.TO) Royal Bank of Canada's Q3 2026 earnings on August 27 will be a key test of whether strong year-to-date growth and stable credit trends can justify the premium valuation around $272.5 and support upside toward $286.00.

  • Sat1Aug

    (Driven by AZN.L) A coordinated US/EU regulatory decision on a major oncology indication expansion for a flagship therapy could unlock a meaningful new revenue stream for AstraZeneca PLC, driving the stock from $13598.09 toward $16000.00 on approval versus a slide toward $16000.00 if regulators delay or reject the filing.

  • Tue30Jun

    (Driven by SU.PA) Schneider Electric’s H1 2026 earnings and updated 2026 guidance will test a rich multiple with the stock near its 52-week high at $276.00; strong orders in electrification, automation and data center power could justify a move toward $295.00, while any slowdown in organic growth or margin compression could trigger a de-rating toward $295.00.

  • Thu18Jun

    (Driven by RY.TO) The market will continue to digest RBC's strong Q2 2026 print and guidance trajectory into the summer, with investors focusing on credit quality, cost of risk, and the sustainability of loan and fee income growth at around $260.54.

Scouting Reports